Obagi-C RX Therapy Night Cream
Gradually diminishes dark spots with 4% hydroquinone, and provides Vitamins C and E to your skin while you sleep.*Valid prescription required. Please see Prescribing Information.
Vitamin C, Vitamin E
*Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
Not available in select states including MA, MT, NH, NY, and TX, due to state regulations regarding the ability of physicians to dispense prescription drug products in their offices. For an effective, cosmetic skin-brightening option, learn about the Obagi-C® Fx System.
Early Intervention for Signs of Skin Damage
With Obagi-C Rx, you’re on your way to softer, smoother, radiant, and more even-looking skin. The Obagi-C Rx System offers 4% hydroquinone to reduce hyperpigmentation, and other key ingredients that help address the signs of skin aging to maintain younger-looking skin.
Obagi-C Rx System products are ideal if you have:
- Hyperpigmentation, sun damage, and age spots
- Uneven skin tone
- Rough skin
- The appearance fine lines and wrinkles
- Dry, normal, or oily skin
Clinically Supported Ingredients
Prescription 4% hydroquinone
- Improves hyperpigmentation (brown spots)
- Provides a lighter, more even-toned complexion
Other key ingredients that address the signs of skin aging
- An exfoliator helps support skin turnover through gentle exfoliation
- 10% L-ascorbic acid (Vitamin C) helps defend against free radicals
- A broad spectrum sunscreen helps protect against harmful UVA and UVB rays
Deep Skin Absorption
When the Obagi-C Rx C-Clarifying Serum with C-Balancing Toner were compared to SkinCeuticals Phloretin CF®, another leading Vitamin C product, more Vitamin C remained in the skin at 24 hours.1,*
*Based on in vitro studies. Clinical significance has not been established.
Reference: 1. Lehman PA, Investigator, Cetero Research. Evaluation of the percutaneous absorption of 14C-ascorbic acid, in vitro, using the Franz human skin finite dose model (protocol R09-0715). Data on file.